MedWatch

Danish cancer vaccine patented in the US

Adaptvac, a joint venture between a Copenhagen University spinout and Danish Expres2ion, has taken out a patent in the US on a new breast cancer vaccine. "An important milestone," says the chairman.

Foto: Colourbox

A new, effective and cheap breast cancer vaccine might be under way for patients with HER2-positive breast cancer, which constitutes 20-30 percent of all breast cancer cases.

The US patent authorities recently allowed the divisional patent for the breast cancer vaccine AV-001 from the biotech company Adaptvac, a 50-50 joint venture between the Copenhagen University spinout Nextgen Vaccines and the Danish biotech company Expres2ion Biotechnologies. The patent is valid in the US for at least 20 years.

Læs hele artiklen

Få 14 dages fri adgang.
Det kræver intet kreditkort.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier